Chiasma: Chiasma's Mycapssa Associated With Positive Patient-Reported Outcomes In Acromegaly Patients

Chiasma Inc (NASDAQ: CHMA) has presented patient-reported outcomes (PROs) data from its MPOWERED Phase 3 trial of Mycapssa for acromegaly, a hormonal disorder in which the pituitary gland produces too much growth hormone. Data demonstrated that study patients reported significantly improved quality of life and work productivity after transitioning from long-acting injectable somatostatin analogs (iSSAs) to Mycapssa. The data were presented at ...Full story available on Benzinga.com